Scarica l'app Stockscreener
6.10
2.52%
0.15
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché FOLD Giù?
Forum
Previsione
Amicus Therapeutics Inc Borsa (FOLD) Ultime notizie
When Will Amicus Therapeutics, Inc. (NASDAQ:FOLD) Turn A Profit? - simplywall.st
Amicus Therapeutics (NASDAQ:FOLD) Hits New 52-Week LowTime to Sell? - MarketBeat
Amicus Therapeutics stock hits 52-week low at 5.79 USD By Investing.com - Investing.com Canada
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives $16.22 Average Price Target from Analysts - MarketBeat
(FOLD) Technical Data - news.stocktradersdaily.com
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Sold by Wedge Capital Management L L P NC - MarketBeat
Amicus Therapeutics: Opportunity Awaits In This Beaten Down Pharma (NASDAQ:FOLD) - Seeking Alpha
Amicus Therapeutics at Goldman Sachs Conference: Strategic Insights Unveiled By Investing.com - Investing.com Canada
Fabry Disease Market to Grow Rapidly During the Study Period (2020–2034) | DelveInsight - Yahoo Finance
Zacks Research Issues Pessimistic Outlook for FOLD Earnings - MarketBeat
Two Sigma Investments LP Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Pompe Disease Therapeutic Market Deep Research Report with - openPR.com
Millennium Management LLC Buys 44,449 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Boosts Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda - GuruFocus
New Strong Sell Stocks for June 3rd - Yahoo Finance
Amicus (FOLD) Reports Positive Findings from PROPEL Study in Pompe Disease | FOLD Stock News - GuruFocus
New Analysis of Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) Published in Muscle and Nerve - GlobeNewswire
Clinical Data Reveals Treatment Advantages: 77% of Pompe Disease Patients Show Improvement with New Therapy - Stock Titan
Two Sigma Advisers LP Acquires 52,000 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Cetera Investment Advisers Takes Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
How to Take Advantage of moves in (FOLD) - news.stocktradersdaily.com
Man Group plc Decreases Stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 - GlobeNewswire
Amicus Therapeutics to Present at Upcoming Investor Conferences in June 2025 | FOLD Stock News - GuruFocus
Rare Disease Leader Amicus Therapeutics to Present Latest Updates at Major Healthcare Conferences - Stock Titan
Millennium Management LLC Has $4.31 Million Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - Defense World
Voloridge Investment Management LLC Sells 397,497 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Squarepoint Ops LLC Purchases 753,060 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Neo Ivy Capital Management Increases Stock Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Woodline Partners LP Sells 726,952 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Shares Purchased by Ameriprise Financial Inc. - Defense World
Pompe Disease Market: Epidemiology, Therapies, Companies, - openPR.com
Teza Capital Management LLC Sells 68,066 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Nuveen Asset Management LLC Purchases 159,139 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Amicus Therapeutics, Inc. (NASDAQ:FOLD) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
297,830 Shares in Amicus Therapeutics, Inc. (NASDAQ:FOLD) Bought by Sovereign s Capital Management LLC - MarketBeat
Vestal Point Capital LP Acquires New Holdings in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Deutsche Bank AG Grows Position in Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
Rafferty Asset Management LLC Sells 73,883 Shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) - MarketBeat
0.68%
0.50%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):